Status:

UNKNOWN

Endocannabinoid Activity Remodulation for Psychosis Liability in Youth

Lead Sponsor:

University of Udine

Collaborating Sponsors:

National Research Council (CNR), Institute of Biomolecular Chemistry (ICB), Italy

Conditions:

Clinical High Risk for Psychosis

Ultra High Risk for Psychosis

Eligibility:

All Genders

18-35 years

Phase:

NA

Brief Summary

Clinical High-Risk (CHR) for Psychosis is characterized by the occurrence of unusual stressful experiences (attenuated psychotic symptoms, APS), anxious symptoms, psychological distress, and substanti...

Detailed Description

1. STATE OF THE ART Among clinical high-risk (CHR) for psychosis individuals, 30-35 % will develop a full-blown disorder after 2-2.5 years. To date there are no proper tools to predict whoever will ev...

Eligibility Criteria

Inclusion

  • Inclusion Criteria
  • Individuals diagnosed with CHR-APS, as defined using CAARMS criteria;
  • Aged 18-35 years;
  • To be able to understand and communicate in Italian;
  • To be able to give informed consent.
  • Exclusion Criteria
  • Lifetime history of a psychotic or manic episode lasting 7 days or longer;
  • Active suicidal ideation indicating significant current risk or history of serious suicide attempt in the opinion of the PI, as evaluated at the screening stage;
  • Lifetime neurological disorders (e.g., epilepsy, except febrile convulsions) or severe intercurrent physical illness;
  • Current treatment with psychotropic medication, with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) stable monotherapy (at least 8 months);
  • Lifetime treatment with antipsychotic medication for more than 7 days;
  • IQ \< 70;
  • Female patients who are pregnant, lactating or not using an acceptable effective form contraception if they are at risk of falling pregnant;
  • Taking part in another pharmacological trial.

Exclusion

    Key Trial Info

    Start Date :

    November 1 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    November 1 2025

    Estimated Enrollment :

    20 Patients enrolled

    Trial Details

    Trial ID

    NCT06037993

    Start Date

    November 1 2022

    End Date

    November 1 2025

    Last Update

    September 21 2023

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    Unit of Psychiatry, University Hospital of Udine

    Udine, UD, Italy, 33100

    2

    Unit of Psychiatry, University Hospital of Udine

    Udine, Italy, 33100